Finanzen von Sophia Genetics SA (SOPH)SOPHSophia Genetics SA

Evaluating the bottom line, SOPHiA GENETICS SA maintains a gross margin of 66.25%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -75.49%, while the net margin is -92.62%. These profitability ratios, combined with a Return on Equity (ROE) of -101.22%, provide a clear picture of how effectively SOPH converts its operational activities into shareholder value.

In the context of the broader market, SOPH competes directly with industry leaders such as WEAV and RZAI. With a market capitalization of $625.69M, it holds a leading position in the sector. When comparing efficiency, SOPH's gross margin of 66.25% stands against WEAV's 72.05% and RZAI's N/A. Such benchmarking helps identify whether SOPHiA GENETICS SA is trading at a premium or discount relative to its financial performance.

SOPH has shown impressive revenue growth, with Q2 2026 revenue at $23.3 million, exceeding expectations and reflecting a 27% increase from the previous year. Despite this, the company continues to report losses, with a net income of -$22.4 million in Q2 2026.